Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)–prescription medications sold under popular drug names like Ozempic and Wegovy–in the United States.
